Effect of the nitrosourea derivative rpcnu (ICIG 1163) on the development of Friend leukemia in mice.
Friend leukemia was used as an experimental model to study the action of a ribofuranosyl derivative of nitrosourea : RPCNU. This new product was known to be active in L 1210 leukemia and immunosuppressive. RPCNU significantly decreases the splenomegaly induced in DBA2 mice by Friend virus when it is given at a time ranging from 7 days before to 14 days after virus inoculation. The survival time in leukemic treated groups is also greatly increased. However, viral content of the spleen extracts of the leukemic treated mice is not reduced. Therefore, RPCNU cannot be considered as an antiviral agent. A comparison between survival of leukemic and non leukemic mice treated with different doses show that the effectiveness of RPCNU is correlated with its toxicity. The effect of RPCNU on Friend leukemia by cytotoxicity on hematopoietic stem cells is discussed in this paper.
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D005260:Female; D005622:Friend murine leukemia virus; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D051379:Mice; D009607:Nitrosourea Compounds / Q000627:therapeutic use* / Q000633:toxicity
D009607:Nitrosourea Compounds